With recent announcements from the WHO, PEPFAR and UNAIDS, there’s much to celebrate. Global leadership now recognizes the need for universal access to ART, while also putting PrEP, VMMC and combination prevention at the core of a comprehensive response. But these targets also highlight current challenges. The coverage gap for ART is wider, and recognition of VMMC comes at a time when scale-up is slowing down. There’s no road map for rolling out PrEP. For AVAC’s take on how the situation for key activities stacks up against a checklist of “must-have” metrics, see below.

**Anatomy of a Target**

**TREATMENT**

- **UNAIDS target (7/2014):** 90 percent of people living with HIV know diagnosis. 90 percent of those are on ART, 90 percent of those are virologically suppressed by 2020.
- **WHO guidance (9/2015):** Immediate offer of ART to all people living with HIV.
- **PEPFAR target (9/2015):** 12.9 million people supported on treatment by the end of 2017. ART has political support, audacious goals and huge potential. But “test and start” is a whole new strategy. There isn’t a clear plan for how to deliver, or accountability if the plan fails.

**PrEP**

- **WHO guidance (9/2015):** Offer of PrEP as a prevention option to all people at substantial risk of acquiring HIV.
- **PEPFAR target (9/2015):** No global PrEP target but included in some DREAMS plans.
- **UNAIDS target (10/2015):** Three million high-need people on PrEP annually. With one global guideline and one country with regulatory approval, the global response is at square one when it comes to meeting the audacious UNAIDS target.

**VMMC**

- **UNAIDS target (10/2015):** Additional 27 million procedures by 2020. The UNAIDS target is audacious and highly measurable. If the world goes at top speed it may even be achievable. But in 2017, PEPFAR’s numbers will fall; who will fill the gap?

**YOUNG WOMEN AND GIRLS**

- **UNAIDS target (10/2015):** 90 percent of women and girls live free from gender-based violence and inequality by 2020.
- **DREAMS** is an initiative from PEPFAR, the Gates Foundation and the Nike Foundation to reduce HIV acquisition in young women and adolescent girls and brings a welcome focus on their sexual and reproductive health needs. But plans shared to date don’t show consistent innovation, and it’s unclear how progress will be measured.

**Status:**

- **Metric is met**
- **Mixed messages—positive signs but no promises**
- **Metric is missing in action**

---

**Pa Wire: A Quarterly Update on HIV Prevention Research | Volume 8 | No.4 | October–December 2015**

**KEY:**